Insider · CIK 0001222012

AFEYAN NOUBAR

Reports to the SEC for 29 companies · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001222012

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-05-21	MRNAModerna, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−9,263 sh	—	—	0
2026-05-21	MRNAModerna, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+9,263 sh	$19.15	+$177K	13,187
2026-05-21	MRNAModerna, Inc.S Sale	Director	SSale	−9,263 sh	$46.84	−$434K	3,924
2026-05-06	MRNAModerna, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+12.9K sh	—	—	12,908
2026-03-02	GENBGenerate Biomedicines, Inc. · Series B Preferred StockC Conversion	Director, 10% Owner	CConversion	−2.11M sh	—	—	0
2026-03-02	GENBGenerate Biomedicines, Inc. · Series B Preferred StockC Conversion	Director, 10% Owner	CConversion	−1.27M sh	—	—	0
2026-03-02	GENBGenerate Biomedicines, Inc. · Series C Preferred StockC Conversion	Director, 10% Owner	CConversion	−1.27M sh	—	—	0
2026-03-02	GENBGenerate Biomedicines, Inc. · Series B Preferred StockC Conversion	Director, 10% Owner	CConversion	−844K sh	—	—	0
2026-03-02	GENBGenerate Biomedicines, Inc. · Series A Preferred StockC Conversion	Director, 10% Owner	CConversion	−1.5M sh	—	—	0
2026-03-02	GENBGenerate Biomedicines, Inc.P Purchase	Director, 10% Owner	PPurchase	+1.56M sh	$16.00	+$25M	15,264,724
2026-03-02	GENBGenerate Biomedicines, Inc. · Series A Preferred StockC Conversion	Director, 10% Owner	CConversion	−17M sh	—	—	0
2026-03-02	GENBGenerate Biomedicines, Inc. · Series B Preferred StockC Conversion	Director, 10% Owner	CConversion	−2.95M sh	—	—	0
2026-03-02	GENBGenerate Biomedicines, Inc.C Conversion	Director, 10% Owner	CConversion	+2.78M sh	—	—	2,777,752
2026-03-02	GENBGenerate Biomedicines, Inc.C Conversion	Director, 10% Owner	CConversion	+987K sh	—	—	987,491
2026-03-02	GENBGenerate Biomedicines, Inc. · Series A Preferred StockC Conversion	Director, 10% Owner	CConversion	−17M sh	—	—	0
2026-03-02	GENBGenerate Biomedicines, Inc.P Purchase	Director, 10% Owner	PPurchase	+1.56M sh	$16.00	+$25M	4,340,252
2026-03-02	GENBGenerate Biomedicines, Inc. · Series B Preferred StockC Conversion	Director, 10% Owner	CConversion	−2.95M sh	—	—	0
2026-03-02	GENBGenerate Biomedicines, Inc. · Series C Preferred StockC Conversion	Director, 10% Owner	CConversion	−2.53M sh	—	—	0
2026-03-02	GENBGenerate Biomedicines, Inc.P Purchase	Director, 10% Owner	PPurchase	+1.56M sh	$16.00	+$25M	1,562,500
2026-03-02	GENBGenerate Biomedicines, Inc.P Purchase	Director, 10% Owner	PPurchase	+1.56M sh	$16.00	+$25M	15,264,724
2026-03-02	GENBGenerate Biomedicines, Inc. · Series C Preferred StockC Conversion	Director, 10% Owner	CConversion	−2.11M sh	—	—	0
2026-03-02	GENBGenerate Biomedicines, Inc.P Purchase	Director, 10% Owner	PPurchase	+1.56M sh	$16.00	+$25M	1,562,500
2026-03-02	GENBGenerate Biomedicines, Inc.C Conversion	Director, 10% Owner	CConversion	+2.78M sh	—	—	2,777,752
2026-03-02	GENBGenerate Biomedicines, Inc. · Series A Preferred StockC Conversion	Director, 10% Owner	CConversion	−18.5M sh	—	—	0
2026-03-02	GENBGenerate Biomedicines, Inc.C Conversion	Director, 10% Owner	CConversion	+2.78M sh	—	—	2,777,752
2026-03-02	GENBGenerate Biomedicines, Inc.C Conversion	Director, 10% Owner	CConversion	+987K sh	—	—	987,491
2026-03-02	GENBGenerate Biomedicines, Inc.C Conversion	Director, 10% Owner	CConversion	+2.78M sh	—	—	2,777,752
2026-03-02	GENBGenerate Biomedicines, Inc. · Series C Preferred StockC Conversion	Director, 10% Owner	CConversion	−2.53M sh	—	—	0
2026-03-02	GENBGenerate Biomedicines, Inc. · Series C Preferred StockC Conversion	Director, 10% Owner	CConversion	−2.11M sh	—	—	0
2026-03-02	GENBGenerate Biomedicines, Inc. · Series C Preferred StockC Conversion	Director, 10% Owner	CConversion	−1.27M sh	—	—	0
2026-03-02	GENBGenerate Biomedicines, Inc. · Series B Preferred StockC Conversion	Director, 10% Owner	CConversion	−2.11M sh	—	—	0
2026-03-02	GENBGenerate Biomedicines, Inc.C Conversion	Director, 10% Owner	CConversion	+12.7M sh	—	—	12,723,940
2026-03-02	GENBGenerate Biomedicines, Inc. · Series B Preferred StockC Conversion	Director, 10% Owner	CConversion	−1.27M sh	—	—	0
2026-03-02	GENBGenerate Biomedicines, Inc. · Series A Preferred StockC Conversion	Director, 10% Owner	CConversion	−1.5M sh	—	—	0
2026-03-02	GENBGenerate Biomedicines, Inc. · Series A Preferred StockC Conversion	Director, 10% Owner	CConversion	−18.5M sh	—	—	0
2026-03-02	GENBGenerate Biomedicines, Inc. · Series B Preferred StockC Conversion	Director, 10% Owner	CConversion	−844K sh	—	—	0
2026-03-02	GENBGenerate Biomedicines, Inc.C Conversion	Director, 10% Owner	CConversion	+13.7M sh	—	—	13,702,224
2026-03-02	GENBGenerate Biomedicines, Inc.C Conversion	Director, 10% Owner	CConversion	+12.7M sh	—	—	12,723,940
2026-03-02	GENBGenerate Biomedicines, Inc.P Purchase	Director, 10% Owner	PPurchase	+1.56M sh	$16.00	+$25M	4,340,252
2026-03-02	GENBGenerate Biomedicines, Inc.C Conversion	Director, 10% Owner	CConversion	+13.7M sh	—	—	13,702,224
2026-02-26	GENBGenerate Biomedicines, Inc. · Stock Option (Right to Buy)A Award	Director, 10% Owner	AAward	+29.6K sh	—	—	29,561
2026-02-26	GENBGenerate Biomedicines, Inc. · Stock Option (Right to Buy)A Award	Director, 10% Owner	AAward	+29.6K sh	—	—	29,561
2025-12-11	MRNAModerna, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−23.9K sh	—	—	0
2025-12-11	MRNAModerna, Inc.S Sale	Director	SSale	−23.9K sh	$29.48	−$703K	3,924
2025-12-11	MRNAModerna, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+23.9K sh	$10.90	+$260K	27,777
2025-04-30	MRNAModerna, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+25.5K sh	—	—	25,512
2024-07-31	MRNAModerna, Inc.S Sale	Director	SSale	−1,309 sh	$121.62	−$159K	2,224,015
2024-07-31	MRNAModerna, Inc.S Sale	Director	SSale	−3,428 sh	$120.88	−$414K	2,225,324
2024-07-31	MRNAModerna, Inc.S Sale	Director	SSale	−4,599 sh	$118.96	−$547K	2,234,416
2024-07-31	MRNAModerna, Inc.S Sale	Director	SSale	−5,664 sh	$119.84	−$679K	2,228,752

Recent filings

Accepted (ET)
May 224
AFEYAN NOUBAR0001193125-26-237309
SEC(opens sec.gov)
May 84
AFEYAN NOUBAR0001682852-26-000084
SEC(opens sec.gov)
Mar 24
AFEYAN NOUBAR0001193125-26-085855
SEC(opens sec.gov)
Mar 24
AFEYAN NOUBAR0001193125-26-085888
SEC(opens sec.gov)

Companies

Address

C/O FLAGSHIP PIONEERING 55 CAMBRIDGE PARKWAY, SUITE 800E

CAMBRIDGE, MA, 02142